INTRODUCTION
The potential for drug name similarity to cause medication errors is widely acknowledged by health care professionals [1] , pharmaceutical manufacturers [2] , safety agencies [3] , professional indemnity insurers [4] and regulators [5, 6] . It is approximated that one-quarter of medication-related incidents voluntarily reported in the United States of America (USA) are caused by drug name confusion [7] .
Research in Australia [8] and the USA [9] has identified numerous factors contributing to drug name confusion, including similarity in the appearance of the drug names (orthography), sound of the drug names (phonology), strengths of the products available, routes of administration, dosage forms of the products, and indications for use. Screening for the similarity of drug names pre-marketing is the best harm-minimisation strategy [10] . However, confusable drug names may only become evident in practice via error and near-miss reports, whereupon clinicians are referred to published lists and warnings [3, 7, [11] [12] [13] .
Researchers in cognitive psychology, linguistics and computer science have developed measures to quantify the orthographic similarity of two drug names [14] [15] [16] . The BI-SIM measure reportedly has the greatest accuracy when predicting drug name confusion [14] . This measure places scoring emphasis on similarities at the beginning of pairs of drug names, assuming that the risk of confusing two names will be increased if they appear in close proximity in a list (e.g. on a computer/device screen) or if products are stored alphabetically in close proximity. BI-SIM scores range from 0.00-1.00.
One initiative to minimise drug confusion errors in clinical practice is the use of Tall Man lettering to distinguish similar drug names [8] . Tall Man lettering uses selective capitalisation to highlight differences among orthographically similar drug names [17] [18] [19] . Acceptability of this technique has been demonstrated in an Australian hospital, with researchers calling for a national list of "look-alike sound-alike" drugs using Tall Man typography [20] .
Overuse of Tall Man lettering may reduce its effectiveness [18] ; as such, it should be reserved for confusable drugs with the greatest potential to cause patient harm, identified through a transparent, reproducible risk-assessment process and based on the best-available evidence.
An evaluation of various Tall Man conventions concluded that the Mid-Tall Man rule was the most effective and most easily applied systematically [21] . This paper reports the development of an evidence-based Australian standard for Tall Man nomenclature, to promote consistency in application of the technique for clinicians, software vendors, regulators and the pharmaceutical industry. Our objectives were to:
1. Develop a comprehensive list of confusable drug name pairs 2. Prioritise confusable drug name pairs for Tall Man representation 3. Apply Tall Man nomenclature to the prioritised drug name pairs.
METHODS

Development of a Comprehensive List of Confusable Drug Name Pairs
A list of confusable drug names, including generic and brand names, was compiled from:  A preliminary list of medications [22] of confusable drugs published in the international literature, and confirmed as marketed brand or generic drug names in Australia  Websites of five medication safety agencies spanning the USA, Europe and Australia  Jurisdictional databases of incidents that involved drug name confusion  Online warnings and alerts published in the 'grey' literature, including incidence reports of drug name confusion from Pharmaceutical Defence Limited, the key pharmacists' indemnity body in Australia.
Prioritisation of Confusable Drug Names for Tall Man Representation
Confusable drugs were prioritised via a risk matrix (Figure 1 1. The 'likelihood of confusion' of the two drugs of interest, assessed using a scoring prototype developed by a multi-disciplinary reference group. Scoring was undertaken by one author (DL) and reviewed by the reference group. To account for factors contributing to confusion between similar drug products, this score arbitrarily comprised:
 Name similarity, as calculated using BI-SIM, using an online calculator [25] The subsequent score was out of 100. Scores were broken into quintiles for application of the risk matrix.
2. The potential severity, or consequence, of confusion between similarly-named drugs, based on clinical judgement of the hypothetical error, and also presented as quintiles in the matrix. Two assumptions were applied: that the exposure to the wrong drug was short term (i.e. that the error was detected within one week), and that the person receiving the wrong drug was otherwise healthy. As confusion between two drug names can occur in either of two directions (i.e. drug A intended but B given, or drug B intended and A given), severity was conservatively based on the direction with the greater potential for harm. The potential severity rating also considered: 
Application of Tall Man Nomenclature
The typography rules of the Mid-Tall Man convention [21] (Figure 2) were applied to the drug name pairs that met criteria for 'extreme' or 'high' risk in the risk matrix. Limitations of this convention were anticipated for larger groups of confusable drug names, such as 10 cephalosporin antibiotics commencing with 'cef' or 'ceph'. In these instances, the name pair with the greatest risk rating (from Figure 1) 'alert fatigue' [8] . The practical limitation of this approach is the exclusion of drug names that may indeed be prone to errors of confusion but with a low risk of patient harm (such as dopamine and dobutamine). Further, the Tall Man convention is not suitable for drugs that may be confused for reasons other than similarity in their names. In both cases, best-practice interventions, such as use of barcode scanners during dispensing [27] [28] [29] and administration [30] , and separation of confusable medicines in storage [8] , are recommended.
Pre-market testing of potentially-confusable drug names may also minimise selection errors by health professionals.
The key assumption behind the compilation of the list of confusable drug names is that errors relating to drug selection have indeed been reported and published [31] [32] [33] [34] . Under-reporting of incidents, and particularly near-misses, is common. It is also possible that reporting systems contain relevant data that are not readily retrievable. Additionally, newer drugs with confusable names may pose a significant risk to patient safety, but may not have been marketed long enough for this risk to have become apparent.
Our application of a similarity score and clinical judgement as two dimensions of a risk matrix is novel. Additional clinical considerations, such as the likelihood that the error would be detected and the frequency with which the error is likely to occur, would enhance the risk assessment; however, these are not easily measured, and the subjectivity would add burden to the clinical judgement. The potential consequence of confusion between two drug products is already, by necessity, a subjective measure, and difficult to judge, as factors such as the duration of exposure to the wrong drug and the patient's co-morbidities, other medicines and overall wellbeing will impact significantly on the outcome. Our use of expert consensus for this variable is a strength of our method, with strong correlation between reviewers' scores.
The limitations in identifying confusable drug names, and in prioritising these drugs for Tall 
